{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:29:00Z","timestamp":1792956540037,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41591-025-03496-y","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:55:46Z","timestamp":1736762146000},"page":"1303-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1522","authenticated-orcid":false,"given":"Robert W.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-2077","authenticated-orcid":false,"given":"Abhishek N.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-6935","authenticated-orcid":false,"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Dobias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh-Quan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-1671","authenticated-orcid":false,"given":"Darius","family":"Babusis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan S.","family":"Vermillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor C.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"3496_CR1","unstructured":"Feldmann, H., Sanchez, A. & Geisbert, T. W. in Fields Virology Vol. 1 (eds Knipe, D. M. & Howley, P. M.) Ch. 32, 923\u2013956 (Lippincott Williams & Wilkins, 2013)."},{"key":"3496_CR2","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1901594","volume":"382","author":"H Feldmann","year":"2020","unstructured":"Feldmann, H., Sprecher, A. & Geisbert, T. W. Ebola. N. Engl. J. Med. 382, 1832\u20131842 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3496_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJMoa051465","volume":"355","author":"DG Bausch","year":"2006","unstructured":"Bausch, D. G. et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 355, 909\u2013919 (2006).","journal-title":"N. Engl. J. Med."},{"key":"3496_CR4","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1128\/JVI.00069-06","volume":"80","author":"JS Towner","year":"2006","unstructured":"Towner, J. S. et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497\u20136516 (2006).","journal-title":"J. Virol."},{"key":"3496_CR5","unstructured":"World Health Organization. Marburg virus disease\u2014Rwanda https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON537 (2024)."},{"key":"3496_CR6","unstructured":"World Health Organization. Ebola: West Africa, March 2014\u20132016 https:\/\/www.who.int\/emergencies\/situations\/ebola-outbreak-2014-2016-West-Africa (2023)."},{"key":"3496_CR7","unstructured":"U.S. Food and Drug Administration. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health (2019)."},{"key":"3496_CR8","unstructured":"European Medicines Agency. New Vaccine for Prevention of Ebola Virus Disease Recommended for Approval in the European Union (2020); https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union_en.pdf"},{"key":"3496_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. REGN-EB3: first approval. Drugs 81, 175\u2013178 (2021).","journal-title":"Drugs"},{"key":"3496_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083429","volume":"14","author":"E Taki","year":"2023","unstructured":"Taki, E. et al. EbangaTM: the most recent FDA-approved drug for treating Ebola. Front. Pharmacol. 14, 1083429 (2023).","journal-title":"Front. Pharmacol"},{"key":"3496_CR11","doi-asserted-by":"publisher","first-page":"e1010805","DOI":"10.1371\/journal.ppat.1010805","volume":"18","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog. 18, e1010805 (2022).","journal-title":"PLoS Pathog."},{"key":"3496_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00985-y","volume":"9","author":"A Marzi","year":"2024","unstructured":"Marzi, A. & Feldmann, H. Filovirus vaccines as a response paradigm for emerging infectious diseases. NPJ Vaccines 9, 186 (2024).","journal-title":"NPJ Vaccines"},{"key":"3496_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"3496_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774026","volume":"12","author":"A Marzi","year":"2021","unstructured":"Marzi, A. et al. Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease. Front. Immunol. 12, 774026 (2021).","journal-title":"Front. Immunol."},{"key":"3496_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq6364","volume":"14","author":"R Hunegnaw","year":"2022","unstructured":"Hunegnaw, R. et al. A single-shot ChAd3\u2013MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci. Transl. Med. 14, eabq6364 (2022).","journal-title":"Sci. Transl. Med."},{"key":"3496_CR16","unstructured":"European Centre for Disease Prevention and Control. Implications of the Marburg Virus Disease Outbreak in Rwanda for the EU\/EEA, 2024 Threat Assessment Brief (2024); https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Marburg-brief-october2024.pdf"},{"key":"3496_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"3496_CR18","unstructured":"SOLIDARITY PARTNERS trial https:\/\/www.isrctn.com\/ISRCTN30355388 (2024)."},{"key":"3496_CR19","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","volume":"66","author":"RL Mackman","year":"2023","unstructured":"Mackman, R. L. et al. Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys. J. Med. Chem. 66, 11701\u201311717 (2023).","journal-title":"J. Med. Chem."},{"key":"3496_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk6176","volume":"383","author":"RW Cross","year":"2024","unstructured":"Cross, R. W. et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science 383, eadk6176 (2024).","journal-title":"Science"},{"key":"3496_CR21","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","volume":"212","author":"TW Geisbert","year":"2015","unstructured":"Geisbert, T. W., Strong, J. E. & Feldmann, H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 212, S91\u2013S97 (2015).","journal-title":"J. Infect. Dis."},{"key":"3496_CR22","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"3496_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539\u2013551 (2020).","journal-title":"J. Clin. Invest."},{"key":"3496_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304876120","volume":"120","author":"RW Cross","year":"2023","unstructured":"Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc. Natl Acad. Sci. USA 120, e2304876120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3496_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001687","volume":"20","author":"DE Griffin","year":"2022","unstructured":"Griffin, D. E. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 20, e3001687 (2022).","journal-title":"PLoS Biol."},{"key":"3496_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/ijms19061575","volume":"19","author":"G Le Menn","year":"2018","unstructured":"Le Menn, G. & Neels, J. G. Regulation of immune cell function by PPARs and the connection with metabolic and neurodegenerative diseases. Int. J. Mol. Sci. 19, 1575 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"3496_CR27","doi-asserted-by":"publisher","first-page":"654960","DOI":"10.3389\/fimmu.2021.654960","volume":"12","author":"Z Ning","year":"2021","unstructured":"Ning, Z., Liu, K. & Xiong, H. Roles of BTLA in immunity and immune disorders. Front. Immunol. 12, 654960 (2021).","journal-title":"Front. Immunol."},{"key":"3496_CR28","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","volume":"9","author":"EA Clark","year":"2018","unstructured":"Clark, E. A. & Giltiay, N. V. CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front. Immunol. 9, 2235 (2018).","journal-title":"Front. Immunol."},{"key":"3496_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s42003-024-06080-1","volume":"7","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Insights on E1-like enzyme ATG7: functional regulation and relationships with aging-related diseases. Commun. Biol. 7, 382 (2024).","journal-title":"Commun. Biol."},{"key":"3496_CR30","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3389\/fimmu.2018.02366","volume":"9","author":"M De Bruyne","year":"2018","unstructured":"De Bruyne, M. et al. A CARD9 founder mutation disrupts NF-\u03baB signaling by inhibiting BCL10 and MALT1 recruitment and signalosome formation. Front. Immunol. 9, 2366 (2018).","journal-title":"Front. Immunol."},{"key":"3496_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2757-z","volume":"587","author":"D Xu","year":"2020","unstructured":"Xu, D. et al. Modulating TRADD to restore cellular homeostasis and inhibit apoptosis. Nature 587, 133\u2013138 (2020).","journal-title":"Nature"},{"key":"3496_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"3496_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159090","volume":"7","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight 7, e159090 (2022).","journal-title":"JCI Insight"},{"key":"3496_CR34","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/infdis\/jiaa290","volume":"222","author":"DP Porter","year":"2020","unstructured":"Porter, D. P. et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus. J. Infec. Dis. 222, 1894\u20131901 (2020).","journal-title":"J. Infec. Dis."},{"key":"3496_CR35","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1128\/JVI.00959-06","volume":"80","author":"KM Daddario-DiCaprio","year":"2006","unstructured":"Daddario-DiCaprio, K. M. et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80, 9659\u20139666 (2006).","journal-title":"J. Virol."},{"key":"3496_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138843","volume":"10","author":"SC Johnston","year":"2015","unstructured":"Johnston, S. C. et al. Dose response of MARV\/Angola infection in cynomolgus macaques following IM or aerosol exposure. PLoS ONE 10, e0138843 (2015).","journal-title":"PLoS ONE"},{"key":"3496_CR37","unstructured":"Study of obeldesivir as postexposure prophylaxis for Marburg virus disease (NCT06682234) https:\/\/clinicaltrials.gov\/study\/NCT06682234?cond=Marburg%20Virus%20Disease&intr=Obeldesivir&rank=1 (2024)."},{"key":"3496_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/2168479016641717","volume":"50","author":"T Allio","year":"2016","unstructured":"Allio, T. Product development under FDA\u2019s animal rule: understanding FDA\u2019s expectations and potential implications for traditional development programs. Ther. Innov. Regul. Sci. 50, 660\u2013670 (2016).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"3496_CR39","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1093\/infdis\/jiz613","volume":"221","author":"AN Prasad","year":"2019","unstructured":"Prasad, A. N. et al. Resistance of cynomolgus monkeys to Nipah and Hendra virus disease is associated with cell-mediated and humoral immunity. J. Infect. Dis. 221, S436\u2013S447 (2019).","journal-title":"J. Infect. Dis."},{"key":"3496_CR40","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/22221751.2022.2086072","volume":"11","author":"C Woolsey","year":"2022","unstructured":"Woolsey, C. et al. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques. Emerg. Microbes Infect. 11, 1635\u20131646 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"3496_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010433","volume":"16","author":"C Woolsey","year":"2022","unstructured":"Woolsey, C. et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl.Trop. Dis. 16, e0010433 (2022).","journal-title":"PLoS Negl.Trop. Dis."},{"key":"3496_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034.1 (2002).","journal-title":"Genome Biol."},{"key":"3496_CR43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0300985813485099","volume":"50","author":"KN Gibson-Corley","year":"2013","unstructured":"Gibson-Corley, K. N., Olivier, A. K. & Meyerholz, D. K. Principles for valid histopathologic scoring in research. Vet. Pathol. 50, 1007\u20131015 (2013).","journal-title":"Vet. Pathol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03496-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:37:42Z","timestamp":1744810662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03496-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3496"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03496-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.C., A.-Q.N., D.B., R.B., M.S.V. and V.C.C. are paid employees of Gilead Sciences, Inc. and may own company stock. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}